Today's Rundown Featured Story | | | Wednesday, April 29, 2020 After dribs and drabs surfacing about Gilead’s COVID-19 hopeful, remdesivir, the first data from a placebo-controlled study are here—at least, an early look at them. Remdesivir cut recovery time for hospitalized COVID-19 patients by four days, or 31%, in an NIH-sponsored study pitting the drug against placebo in more than 1,000 patients. |
|
|---|
|
Top Stories Wednesday, April 29, 2020 Biopharma players worldwide have committed big money and talent to the hunt for a COVID-19 vaccine, and experts predict a shot might be available in 12 to 18 months. Behind the scenes, the Trump administration is working up a Manhattan Project-type initiative to further accelerate the work, Bloomberg reports. Wednesday, April 29, 2020 U.S. tech giants have quickly brought their innovations to the front lines amid COVID-19. Find out how Amazon, Apple and Google are racing to use their technologies and services to battle the novel coronavirus. Wednesday, April 29, 2020 Johnson & Johnson, one of a wave of companies racing to produce a vaccine for the novel coronavirus, aims to sign up a network of manufacturing partners to help boost capacity ahead of a potential FDA approval. Now, in its second sweeping production deal, J&J has paired up with Catalent to set the stage for the shot's debut. Wednesday, April 29, 2020 Pfizer and partner BioNTech are keeping pace with the speed of the sweeping pandemic as they finish dosing in the first cohort of their COVID-19 inoculation test. Wednesday, April 29, 2020 Weeks after launching their own COVID-19 molecular testing initiatives, lab giants Quest Diagnostics and LabCorp have begun offering antibody tests nationwide for the next phase of the coronavirus pandemic. Tuesday, April 28, 2020 With mounting concerns about safety and the financial security of physicians during COVID-19, organizers say the new group called United Physicians will take advantage of virtual platforms to pull together a large number around the issues they most care about. Wednesday, April 29, 2020 The COVID-19 pandemic didn't have a major impact on the insurer's first-quarter earnings, but that could change in the months ahead. Wednesday, April 29, 2020 Much of the rush to create capacity among the surges of novel coronavirus cases centered on reworking hospital units or quickly building out field hospitals. Tufts Medical Center in Boston is looking to a different answer: offering hospital-level acute care in patients' homes. Wednesday, April 29, 2020 When the novel coronavirus put China on high alert, there were concerns that the outbreak would hit AstraZeneca hard, given its high exposure to the country. But the company managed to grow sales ahead of expectations, thanks to its oncology portfolio and respiratory med Symbicort. Wednesday, April 29, 2020 Though its first-quarter sales were up—due in no small part to the closure of its $4.2 billion acquisition of BTG last year—Boston Scientific’s total net income shrank down to a slim margin compared to 2019’s lead-off quarter. Wednesday, April 29, 2020 House lawmakers are pressing leadership to include in the next financial relief package new flexibility for hospitals to keep their 340B eligibility. Wednesday, April 29, 2020 Wellness visits, including vaccinations, have plummeted in the time of COVID-19, GlaxoSmithKline acknowledged Wednesday. But how much will that affect its high-flying shingles vaccine Shingrix? Executives downplayed the impact and laid out a plan for restarting demand for the shot, its fastest-growing product, later this year. |
|
.png)
